Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Astellas Squeaks Out Sales Rise as FX, Mainstay Growth Offset Generic Hit
Astellas Pharma eked out a 0.6% increase in revenue in the first half of FY2023 as the tailwind of the depreciated yen and robust sales of major products barely offset the negative impact of Lexiscan (regadenoson) generic erosions in the…
To read the full story
Related Article
- Astellas Beats H1 Forecast on Strategic Product Growth, Cost Controls
October 31, 2025
- Astellas Assembles Task Team to Assess US Tariff Risks
July 31, 2025
- Astellas Gears Up for Xtandi Patent Cliff with Next-Gen Assets, Cost Cuts
April 28, 2025
- Astellas Records 22% Revenue Growth in 1H Riding on Strategic Assets
October 31, 2024
- Xtandi’s Global Sales Surge Nearly 30% in April-June: Astellas
August 2, 2024
- Astellas’ FY2023 Operating Profit Tumbles 80% Due to Iveric Bio Buyout
April 26, 2024
- Astellas Slashes FY2023 Profit Forecasts on Gene Therapy Impairment Loss
April 15, 2024
- Astellas Slashes FY2023 Veozah Forecast as Vertical Start-Up Plan Stumbles
February 6, 2024
- Astellas’ Q1 Sales Skid on Lexiscan Generic Erosion, but Full-Year Growth Expected with Hot Flash Med
August 2, 2023
BUSINESS
- FRONTEO to Back Biotech Startups with AI and Capital as Third Biz Leg
February 13, 2026
- Biomedix Takes Over Originator Data as Generics Face Supply, Information Challenge
February 13, 2026
- Datroway Filed for 1st-Line TNBC in Japan: Daiichi Sankyo
February 13, 2026
- Nxera Gets US$1.8 Million Early-Stage Milestone from Centessa
February 13, 2026
- Nxera Licenses GPCR Program to European VC-Backed Startup
February 13, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…